Preeclampsia is a serious cardiovascular complication in pregnancy which is characterized by hypertension, proteinuria, and endothelial dysfunction. After a preeclamptic pregnancy, mother and newborn have a significantly increased future risk for metabolic and cardiovascular diseases. 1 Interestingly, preeclampsia shares risk factors with the metabolic syndrome including insulin resistance and obesity. 1 The mechanisms underlying preeclampsia have been better elucidated in recent years. Thus, dysregulation of various circulating factors influencing angiogenesis, body weight, and insulin sensitivity is an important pathogenetic element of the disease. Among those, antiangiogenic proteins including soluble fms-like tyrosine kinase (sflt) 1 and endoglin are significantly increased in preeclampsia and contribute to blood pressure upregulation, as well as impaired uterine perfusion. [2] [3] [4] [5] [6] [7] Furthermore, dysregulation of angiopoietin (Ang)-1 and -2 has been demonstrated in preeclampsia. Thus, the increase of serum Ang-2, a natural antagonist of Ang-1, during normal pregnancy was suppressed in women with preeclampsia. 8 In addition, serum sflt1/Ang-2 ratio was significantly elevated in preeclamptic patients and differentiated preeclamptic women from healthy pregnant controls with excellent specificity and sensitivity. 9 In accordance with these findings, placentae obtained from women with preeclampsia had reduced levels of Ang-2 mRNA. 10 In contrast to Ang-2, Ang-1 plasma levels were significantly increased in preeclampsia. 11 Furthermore, increased concentrations of the appetite-suppressive adipocyte-derived protein leptin are found in preeclampsia before clinical onset of the disease. 12 Moreover, insulin resistance-inducing tumor necrosis factor-α is elevated approximately twofold in women with preeclampsia 13 and significantly increases mean arterial pressure in rats. 14 Recently, liver-derived angiopoietin-related growth factor (AGF, also known as Angptl6) has been introduced as a novel circulating protein which significantly influences angiogenesis 15 but also body weight and insulin sensitivity. 16 Thus, transgenic mice expressing AGF in epidermal keratinocytes exhibited reddish ears, snouts, and soles of feet compared to control mice suggesting enhanced angiogenesis in the skin tissues. 15 In accordance with this hypothesis, the density of capillary-like vessels was increased in the transgenic animals. 15 Furthermore, AGF-induced neovascularisation was demonstrated in vivo by mouse corneal and matrigel plug assays. 15 
Background
Preeclampsia is a serious complication in pregnancy with an increased future cardiovascular and metabolic risk for both mother and newborn. recently, angiopoietin-related growth factor (aGF) was introduced as a novel liver-derived protein with proangiogenic and insulin-sensitizing effects. In the current study, we hypothesized that serum levels of aGF would be lower in preeclamptic patients as compared to healthy controls.
Methods
aGF was quantified by enzyme-linked immunosorbent assay (ELISa) in control and preeclamptic patients during pregnancy (control: n =22, Preeclampsia: n =22) and 6 months after delivery (control: n =20, Preeclampsia: n =20). Furthermore, circulating aGF was correlated to clinical and biochemical measures of renal function, glucose, and lipid metabolism, as well as inflammation.
results
During pregnancy, median maternal aGF concentrations were significantly higher in preeclampsia (191.6 µg/l) as compared to control subjects (136.3 µg/l) (P = 0.004). Furthermore, preeclampsia and systolic blood pressure (SBP) were associated with aGF levels in multivariate analyses independent of maternal age. however, higher circulating aGF concentrations in preeclampsia did not persist 6 months after delivery.
conclusions Maternal aGF serum levels are significantly and paradoxically higher in preeclampsia during pregnancy. however, median postpartum circulating aGF levels are similar in preeclampsia and normal pregnancies. 
articles

AGF and Preeclampsia
In addition, AGF-deficient mice developed marked obesity and insulin resistance, as well as lipid accumulation in skeletal muscle and liver, which was accompanied by reduced energy expenditure. 16 In accordance with these results, rodents with transgenic overexpression of AGF were lean, insulin-sensitive, and showed increased energy expenditure. 16 Furthermore, mice overexpressing AGF were resistant to high-fat dietinduced obesity, insulin resistance, and nonadipose tissue steatosis. 16 Similar effects were also found in animals with hepatic overexpression of AGF by adenoviral transduction. 16 In contrast to other circulating factors influencing angiogenesis, body weight, and insulin sensitivity including sflt1, endoglin, Ang-1, -2, leptin, as well as tumor necrosis factor-α, AGF serum concentrations have not been evaluated so far in pregnancies with preeclampsia. We hypothesized that circulating AGF would be lower in preeclamptic patients similar to other proangiogenic factors including placental growth factor. 17 We determined AGF levels in 22 control and 22 preeclamptic patients and correlated serum concentrations of this circulating factor to clinical and biochemical measures of renal function, glucose, and lipid metabolism, as well as inflammation. Furthermore, AGF was measured in most of the patients 6 months after delivery.
Methods
Subjects. Twenty-two Caucasian pregnant women with preeclampsia were recruited from the Department of Obstetrics, University of Leipzig with none of the women having episodes of preeclampsia in a prior pregnancy. The control group consisted of 22 normotensive pregnant Caucasian women who were admitted to the Department of Obstetrics of the University of Leipzig for indications including cervical insufficiency and placenta previa. Preeclampsia was defined as gestational blood pressure elevation >140 mm Hg systolic or >90 mm Hg diastolic accompanied by proteinuria in women who were normotensive before 20 weeks of gestation according to the Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. 18 Significant proteinuria was defined as ≥300 mg total protein in a 24-h urine collection or ≥1+ proteinuria by dipstick in a random urine analysis with no evidence of urinary tract infection. BMI was calculated as weight before pregnancy divided by squared height. Age ranged from 18 to 40 years and BMI from 16.9 to 30.5 kg/m 2 . Homeostasis model assessment of insulin resistance was determined as previously described. 19 Study protocol. In all patients, blood was obtained after an overnight fast within 3 days of admittance to the Department of Obstetrics, University of Leipzig. In the preeclamptic patients, blood was drawn within three days of the diagnosis of preeclampsia. At the time of the blood sampling, none of the women was in labor. Serum was separated immediately by centrifugation at 4,000 g for 10 min and frozen at -80 °C.
Patients with renal diseases, diabetes mellitus, malignant diseases, a body temperature above 38.5 °C or signs of sepsis at first presentation were excluded from the study. The study was approved by the local Ethics Committee. All subjects gave written informed consent before taking part in the study.
Serum was also obtained from 20 of 22 controls and 20 of 22 preeclamptic patients ~6 months after delivery (median; total sample: 194 days; Controls: 200 days; Preeclampsia: 185 days; P = 0.39 for Control vs. Preeclampsia). Four patients (2 Controls, 2 Preeclampsia) of the original study declined to take part in the follow-up or could not be reached.
Assays. Serum insulin was measured with a two-site chemiluminescent enzyme immunometric assay for the Immulite automated analyzer (Diagnostic Products, Los Angeles, CA). Leptin (Mediagnost, Reutlingen, Germany), adiponectin (Mediagnost, Reutlingen, Germany), and AGF (Adipogen, Seoul, South Korea) serum concentrations were determined with commercially available enzyme-linked immunosorbent assays (ELISAs) according to the manufacturers' instructions. The sensitivity of the AGF ELISA was 1.2 µg/l. While the degree of precision of the ELISA system in terms of coefficient of variance (%) of intra-assay was between 1.5 and 3.3%, that of inter-assays was between 3.3 and 8.6%. Spike recovery and linearity were in a range of 85-105% and 96-101%, respectively. The ELISA was specific for human AGF with no detectable crossreactivities to human adiponectin, resistin, fatty acid-binding protein-4, vaspin, visfatin, retinol-binding protein-4, as well as angiopoietin-like protein-3, -4, and -7. Levels of creatinine, glucose, cholesterol, triglycerides, and C-reactive protein were measured by standard laboratory methods in a certified laboratory.
Statistical analysis. SPSS software version 11.5 (SPSS, Chicago, IL) was used for all statistical analyses. Distribution was tested for normality using Shapiro-Wilk W-test and all non-normally distributed parameters were logarithmically transformed before performing parametric tests. Differences between control and preeclamptic patients were assessed by unpaired Student's t-test or χ 2 -test. Correlations were performed using the Pearson's correlation method. To adjust the effects of covariates and identify independent relationships, multivariate linear regression analyses were performed. Differences in AGF serum levels before and 6 months after delivery were assessed by paired Student's t-test. A P value of < 0.05 was considered as statistically significant in all analyses. results agF serum levels are significantly higher in preeclamptic patients as compared to controls Clinical characteristics of the subgroups studied (Control, Preeclampsia) are summarized in Table 1 . Maternal serum AGF concentrations were significantly higher in preeclamptic patients as compared to control subjects ( Table 1) . Age, BMI, and gestational age at blood sampling were not significantly different in the two groups; however, there was a trend toward higher age and BMI in the preeclamptic group ( Table 1 ). The significant difference in circulating AGF between control and preeclamptic patients was also seen after adjustment for articles AGF and Preeclampsia maternal age and BMI (P < 0.05) (data not shown). Systolic blood pressure (SBP) and diastolic blood pressure (DBP), serum creatinine, triglycerides, leptin, adiponectin, and C-reactive protein were significantly higher in preeclamptic patients as compared to healthy pregnant controls ( Table 1) . In contrast, fasting glucose, fasting insulin, homeostasis model assessment of insulin resistance, and cholesterol were not different between the two groups ( Table 1) .
univariate correlations
When all patients were studied, serum AGF levels positively correlated with blood pressure (SBP, DBP), creatinine, and C-reactive protein ( Table 2) . In preeclamptic patients, a positive correlation between AGF and C-reactive protein was also present ( Table 2) . However, all other significant univariate correlations were lost when the two subgroups were studied separately ( Table 2) . Because proteinuria was assessed by dipstick only in most of the women, we could not assess the correlation between 24-h urine proteinuria and AGF in the current study.
Multivariate correlations
Multiple regression analysis revealed that the positive association between AGF and SBP remained significant after adjustment for maternal age (Table 3, model 1) . Furthermore, preeclampsia was a predictor of circulating AGF independent articles AGF and Preeclampsia of maternal age (Table 3 , model 2). In contrast, the association of AGF with creatinine (Table 3 , model 3) and C-reactive protein (data not shown) was lost after controlling for SBP and age.
agF serum levels 6 months after delivery
Finally, AGF serum levels were studied in 20 of 22 controls and 20 of 22 preeclamptic patients ~6 months after delivery. Median AGF serum levels were not significantly different in the control women after delivery (137.3 µg/l (25th percentile, 75th percentile: 101.7, 167.7)) as compared to the concentrations during pregnancy (140.0 µg/l (113.6, 171.3)) (P = 0.51).
In contrast, AGF serum concentrations significantly decreased in the preeclamptic patients studied from 191.0 µg/l (158.3, 222.0) during pregnancy to 105.5 µg/l (63.5, 197.7) 6 months after delivery (P = 0.004). Postpartum AGF levels were similar between controls (137.3 µg/l (101.7, 167.7)) and preeclamptic patients (105.5 µg/l (63.5, 197.7)) (P = 0.37).
discussion
Strong evidence has been presented recently that downregulation of proangiogenic mediators such as placental growth factor and induction of antiangiogenic proteins such as sflt1 contribute to the pathogenesis of preeclampsia. [2] [3] [4] [5] [6] [7] 17 In the current study, we demonstrate for the first time that maternal serum AGF levels are significantly higher in preeclamptic patients as compared to healthy controls. Furthermore, preeclampsia is a significant predictor of circulating AGF in multivariate analysis independent of age. Moreover, SBP is significantly associated with AGF concentrations in multivariate analysis. However, since all preeclamptic subjects have a higher SBP than controls by definition, the SBP may be merely a marker for preeclamptic status or vice versa. Upregulation of AGF in preeclampsia appears paradoxical because this liverderived protein has potent proangiogenic properties. Thus, adenovirus-mediated AGF overexpression in ischemic limb increases blood flow through induction of angiogenesis and arteriogenesis, thereby, reducing the necessity for limb amputation. 20 Additional in vitro and in vivo experiments by the same authors demonstrate convincingly that this effect is mediated via increased nitric oxide production through activation of p44/42 mitogen-activated protein kinase and endothelial nitric oxide synthase signaling. 20 It needs to be determined in future studies whether AGF upregulation in preeclampsia might be a compensatory mechanism to counteract impaired nitric oxide availability and angiogenesis in preeclampsia. Furthermore, it should be assessed whether elevated serum levels of AGF in preeclampsia are derived from placenta. Convincing evidence has been presented that AGF potently antagonizes obesity and insulin resistance besides its proangiogenic properties 16 and is a candidate gene for obesity in mice on atherogenic diet. 21 Furthermore, suppression of glucose production in hepatocytes has been suggested as a mechanism for glucose-lowering effects of AGF. 22 In the current study, circulating AGF is not independently related to markers of obesity, glucose, and lipid metabolism. These results do not support the hypothesis that AGF is a major factor influencing body weight and insulin sensitivity in humans. However, further studies in larger and nonpregnant populations are necessary to better elucidate the potential role of AGF in facets of the metabolic syndrome. Unstandardized β-coefficients, 95% confidence intervals for unstandardized β-coefficients, and P values are given; (log) indicates parameters which were logarithmically transformed before multivariate analysis. AGF, angiopoietin-related growth factor; SBP, systolic blood pressure. 
